The FDA removed BPC-157 from Category 2 (substances raising significant safety concerns for compounding) in April 2026 after nominations were withdrawn, following a February 2026 announcement by HHS regarding multiple peptides. On July 23, 2026, the Pharmacy Compounding Advisory Committee narrowly voted 8-6 (one abstention) to recommend BPC-157 for the 503A Bulks List, overriding agency staff opposition, alongside similar narrow approvals for related peptides. This advisory step supports potential reclassification to Category 1, which would permit licensed compounding pharmacies to prepare it under physician prescription, but does not equate to drug approval or immediate legal authority. Final FDA placement requires formal notice-and-comment rulemaking, a process typically spanning several additional months. BPC-157 remains unapproved for any medical use, with ongoing evaluation focused on immunogenicity risks and limited human data.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วใหม่
Aug 31, 2026
August 31, 2026
13%
December 31, 2026
49%
$2,649 ปริมาณ
August 31, 2026
$943 ปริมาณ
13%
December 31, 2026
$1,706 ปริมาณ
49%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA removed BPC-157 from Category 2 (substances raising significant safety concerns for compounding) in April 2026 after nominations were withdrawn, following a February 2026 announcement by HHS regarding multiple peptides. On July 23, 2026, the Pharmacy Compounding Advisory Committee narrowly voted 8-6 (one abstention) to recommend BPC-157 for the 503A Bulks List, overriding agency staff opposition, alongside similar narrow approvals for related peptides. This advisory step supports potential reclassification to Category 1, which would permit licensed compounding pharmacies to prepare it under physician prescription, but does not equate to drug approval or immediate legal authority. Final FDA placement requires formal notice-and-comment rulemaking, a process typically spanning several additional months. BPC-157 remains unapproved for any medical use, with ongoing evaluation focused on immunogenicity risks and limited human data.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
ตลาดเปิดเมื่อ: Jun 22, 2026, 10:10 PM ET
ปริมาณการซื้อขาย
$2,649วันสิ้นสุด
Dec 31, 2026ตลาดเปิดเมื่อ
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA removed BPC-157 from Category 2 (substances raising significant safety concerns for compounding) in April 2026 after nominations were withdrawn, following a February 2026 announcement by HHS regarding multiple peptides. On July 23, 2026, the Pharmacy Compounding Advisory Committee narrowly voted 8-6 (one abstention) to recommend BPC-157 for the 503A Bulks List, overriding agency staff opposition, alongside similar narrow approvals for related peptides. This advisory step supports potential reclassification to Category 1, which would permit licensed compounding pharmacies to prepare it under physician prescription, but does not equate to drug approval or immediate legal authority. Final FDA placement requires formal notice-and-comment rulemaking, a process typically spanning several additional months. BPC-157 remains unapproved for any medical use, with ongoing evaluation focused on immunogenicity risks and limited human data.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
ปริมาณการซื้อขาย
$2,649วันสิ้นสุด
Dec 31, 2026ตลาดเปิดเมื่อ
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The FDA removed BPC-157 from Category 2 (substances raising significant safety concerns for compounding) in April 2026 after nominations were withdrawn, following a February 2026 announcement by HHS regarding multiple peptides. On July 23, 2026, the Pharmacy Compounding Advisory Committee narrowly voted 8-6 (one abstention) to recommend BPC-157 for the 503A Bulks List, overriding agency staff opposition, alongside similar narrow approvals for related peptides. This advisory step supports potential reclassification to Category 1, which would permit licensed compounding pharmacies to prepare it under physician prescription, but does not equate to drug approval or immediate legal authority. Final FDA placement requires formal notice-and-comment rulemaking, a process typically spanning several additional months. BPC-157 remains unapproved for any medical use, with ongoing evaluation focused on immunogenicity risks and limited human data.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย